Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Sousa HT, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Cornillie F, Lopes J, Carneiro F; Portuguese IBD Group [GEDII]. Magro F, et al. Among authors: ramos j. J Crohns Colitis. 2019 Oct 28;13(11):1387-1393. doi: 10.1093/ecco-jcc/jjz071. J Crohns Colitis. 2019. PMID: 30989180 Clinical Trial.
Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II).
Durães C, Machado JC, Portela F, Rodrigues S, Lago P, Cravo M, Ministro P, Marques M, Cremers I, Freitas J, Cotter J, Tavares L, Matos L, Medeiros I, Sousa R, Ramos J, Deus J, Caldeira P, Chagas C, Duarte MA, Gonçalves R, Loureiro R, Barros L, Bastos I, Cancela E, Moraes MC, Moreira MJ, Vieira AI, Magro F. Durães C, et al. Among authors: ramos j. Inflamm Bowel Dis. 2013 Feb;19(2):230-9. doi: 10.1002/ibd.23007. Inflamm Bowel Dis. 2013. PMID: 22573572
Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Dias CC, Magro F; Portuguese IBD Study Group (GEDII). Afonso J, et al. Among authors: ramos j. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. Aliment Pharmacol Ther. 2016. PMID: 27507790
Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Coelho R, Tavares P, Soares J, Sousa AL, Carvalho D, Sousa P, da Silva JP, Meira T, Silva Ferreira F, Dias CC, Chowers Y, Ben-Horin S, Magro F; on behalf Portuguese IBD Study Group (GEDII). Afonso J, et al. Among authors: ramos j. Therap Adv Gastroenterol. 2016 Nov;9(6):781-794. doi: 10.1177/1756283X16658223. Epub 2016 Jul 26. Therap Adv Gastroenterol. 2016. PMID: 27803733 Free PMC article.
The who-when-why triangle of CAM use among Portuguese IBD patients.
Portela F, Dias CC, Caldeira P, Cravo M, Deus J, Gonçalves R, Lago P, Morna H, Peixe P, Ramos J, Sousa H, Tavares L, Vasconcelos H, Magro F, Ministro P. Portela F, et al. Among authors: ramos j. Dig Liver Dis. 2017 Apr;49(4):388-396. doi: 10.1016/j.dld.2016.12.031. Epub 2017 Jan 6. Dig Liver Dis. 2017. PMID: 28117198
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.
Magro F, Afonso J, Lopes S, Coelho R, Gonçalves R, Caldeira P, Lago P, de Sousa HT, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Andrade P, Soares JB, Carvalho D, Sousa P, Meira T, Lopes J, Moleiro J, Dias CC, Falcão A, Geboes K, Carneiro F; Portuguese IBD Study Group (GEDII). Magro F, et al. Among authors: ramos j. EBioMedicine. 2017 Jul;21:123-130. doi: 10.1016/j.ebiom.2017.06.004. Epub 2017 Jun 7. EBioMedicine. 2017. PMID: 28629912 Free PMC article.
Clinical performance of an infliximab rapid quantification assay.
Magro F, Afonso J, Lopes S, Coelho R, Gonçalves R, Caldeira P, Lago P, de Sousa HT, Ramos J, Gonçalves AR, Ministro P, Rosa I, Meira T, Andrade P, Soares JB, Carvalho D, Sousa P, Vieira AI, Lopes J, Dias CC, Geboes K, Carneiro F. Magro F, et al. Among authors: ramos j. Therap Adv Gastroenterol. 2017 Sep;10(9):651-660. doi: 10.1177/1756283X17722916. Epub 2017 Aug 11. Therap Adv Gastroenterol. 2017. PMID: 28932267 Free PMC article.
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.
Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Magro F, et al. Among authors: ramos j. Therap Adv Gastroenterol. 2019 Aug 30;12:1756284819869141. doi: 10.1177/1756284819869141. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31516554 Free PMC article.
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
3,767 results